Infectious Disease Therapeutics Market Overview, Growth, Trends, Analysis, Research Report (2020-2030)

The infectious disease therapeutics market size in 2022 stood at US$ 1,19,708.77 million and is projected to reach US$ 1,67,883.93 million by 2030. The market is expected to register a CAGR of 4.30% during 2022–2030. Rising number of product approvals and launches is likely to remain key trends in the market.

Infectious Disease Therapeutics Market Analysis

The rising prevalence of infectious diseases in society, the market players have released advanced medicines for the treatment of infectious disorders, the initiatives taken by the government to provide individuals with sophisticated facilities for the treatment of infectious diseases is driving the market.

Infectious Disease Therapeutics Market Overview

Bacteria, viruses, fungus, and parasites are all creatures that cause infectious diseases. Antibiotics, antivirals, and antiparasitics are some of the medications used to treat infectious disorders. Therapeutics for infectious diseases could act directly on organisms or aid the body's immune system in fighting infections. Infectious diseases include HIV, tuberculosis, malaria, hepatitis, and influenza, among others.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Infectious Disease Therapeutics Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Infectious Disease Therapeutics Market Drivers and Opportunities

Increasing Focus on Funding and R&D in Infectious Disease Therapeutics to Favor Market Growth

Research and development (R&D) is a important part of the business of pharmaceutical companies and biopharmaceuticals. R&D allows the companies to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.

The table below displays the annual funding for various disease categories and research on the basis of contracts, grants, and other funding mechanisms used across the National Institutes of Health (NIH).

Diseases and Funding

Disease/Research Areas	2019 (US$ Millions)	2020 (US$ Millions)	2021 (US$ Millions)	2022 (US$ Millions)
Emerging Infectious Diseases	2,950	4,867	5,069	4,318
Infectious Diseases	6,313	8,301	8,599	8,019
Sexually Transmitted Infections	354	394	404	419

Note: Current conversion rate is considered for the currencies.

Source: Annual Reports and The Insight Partners Analysis

The major projects that the manufacturers have funded:

• In June 2022, GSK plc invested US$ 1.21 billion (£1 billion) over 10 years to expedite research and development (R&D) focused on infectious diseases that disproportionately affect low-income nations. The research will concentrate on new medicines and disruptive vaccines to prevent and treat malaria, tuberculosis, HIV (via ViiV Healthcare), neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).

• In March 2022, the Global Fund's COVID-19 Response Mechanism (C19RM) received  a donation of US$ 48.07 million (CAD 60 million) from Canada which was praised by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The new funds was used to offer low- and middle-income countries with vital treatments and diagnostic tests, including medical oxygen, and personal protective equipment (PPE).

Thus, rising focus on R&D and funding is driving the infectious disease therapeutics market growth.

Growing Opportunities in Developing Nations

The rising prevalence of infectious diseases is anticipated to improve sales of infectious disease treatment medications in emerging countries. Because of the lower data requirements and stricter laws, Asia Pacific has emerged as a flexible and business-friendly region. Furthermore, large investments in health research and life science in emerging countries play an important role in supporting cutting-edge technology in developing countries, which in turn encourages the trend towards infectious disease detection and treatment. For example, UNAIDS is calling for a US$ 29 billion investment by 2025 to satisfy the AIDS prevention and treatment needs of low- and middle-income countries. In India, South Korea, Brazil, and Mexico, infectious diseases such as Hepatitis, HAI, HIV, and influenza are prevalent; there is a big patient population; disposable money has increased; healthcare infrastructure has improved; and medical tourism is expanding. Thus, essential infectious disease therapeutics product producers in expanding infectious disease therapeutics markets in these nations should expect profitable prospects in the future.

Infectious Disease Therapeutics Market Report Segmentation Analysis

Key segments that contributed to the derivation of the infectious disease therapeutics market analysis are drug class, indication, route of administration, distribution channel.

• Based on drug class, the infectious disease therapeutics market is divided into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
• By indication, the market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest share of the market in 2022.
• In terms of route of administration, the market is segmented into a oral, parenteral, topical, and others. The oral manufacturers segment held the largest share of the market in 2022.
• Based on distribution channel, the infectious disease therapeutics market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

Infectious Disease Therapeutics Market Share Analysis by Geography

The geographic scope of the infectious disease therapeutics market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.

North America has dominated the market. Growing adoption of technological advancements and rising research and development activities are projected to accelerate the growth of the infectious disease therapeutics market. Moreover, large healthcare businesses and the rising demand for advanced therapeutic solutions to treat chronic conditions and viral diseases are propelling the market expansion in this region.

Infectious Disease Therapeutics Market Regional Insights

The regional trends and factors influencing the Infectious Disease Therapeutics Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Infectious Disease Therapeutics Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Infectious Disease Therapeutics Market Report Scope

Infectious Disease Therapeutics Market Players Density: Understanding Its Impact on Business Dynamics

The Infectious Disease Therapeutics Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Infectious Disease Therapeutics Market are:

1. Pfizer Inc
2. Gilead Sciences Inc
3. F. Hoffmann-La Roche Ltd
4. Shionogi & Co Ltd
5. Bayer AG
6. BioCryst Pharmaceuticals Inc

Disclaimer: The companies listed above are not ranked in any particular order.

Infectious Disease Therapeutics Market News and Recent Developments

The infectious disease therapeutics market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the infectious disease therapeutics market are listed below:

• Roche launched the first infectious disease tests and cobas omni–Utility Channel for use on the cobas 5800 System in countries accepting the CE Mark. The cobas omni–Utility Channel on the cobas 5800 System enables a broader testing menu by consolidating open channel assays with Roche in vitro diagnostic (IVD) assays on a single platform. (Source: F. Hoffmann-La Roche Ltd, Press Release, December 2022)

Infectious Disease Therapeutics Market Report Coverage and Deliverables

The “Infectious Disease Therapeutics Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:

• Infectious disease therapeutics market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Infectious disease therapeutics market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• infectious disease therapeutics market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the infectious disease therapeutics market
• Detailed company profiles